To include your compound in the COVID-19 Resource Center, submit it here.

A-623: Phase IIb ongoing

Anthera disclosed in its 2Q11 earnings that a DSMB recommended continuation of the double-blind, international Phase IIb PEARL-SC trial

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE